# Farletuzumab-exatecan

Source: https://onco.cc/drugs/farletuzumab-exatecan/  
OnCo record `farletuzumab-exatecan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.

## Summary

Farletuzumab-exatecan (SYS6041) is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is Folate receptor alpha (the sponsor names Folate receptor alpha (FRα)). The sponsor states: SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle. ClinicalTrials.gov describes the intervention as: Farletuzumab-exatecan antibody-drug conjugate targeting human FRα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07744763, plans to enrol 260 participants with primary completion expected 2027-03-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: SYS6041
- Modality: ADC
- Mechanism: SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle.

## Sources

- ClinicalTrials.gov: trials of Farletuzumab-exatecan: https://clinicaltrials.gov/search?intr=Farletuzumab-exatecan

## Connected records

- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- trials: [A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer](https://onco.cc/trials/nct07714668/), [A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07744763/)

---
JSON: https://onco.cc/api/v1/entities/farletuzumab-exatecan.json